Document is current

Article History

Received: 12 January 2022

Revised: 14 June 2022

Accepted: 12 October 2022

First Online: 19 January 2023

Declarations

:

: Research use of human tissues: The cadaveric donor eyes were exempt from IRB. Research use of mice was approved by the IACUC of Ora, Inc. (approval # 2020-03-09).

: Written informed consent for publication of their clinical details and/or clinical images was obtained from the patients. A copy of the consent form is available for review by the Editor of this journal.

: The author RRY is a BCD patient and the founder, CEO, and key shareholder of Reflection Biotechnologies Limited (ReflectionBio®). ReflectionBio® is a patient-driven biotechnology company which applies the <i>By Patients, For Patients</i>™ approach for patients to play a proactive role in driving rare disease research and orphan drug development. The content of this Article represents the author’s personal view as a patient and does not represent that of ReflectionBio®. ReflectionBio® has filed a patent application related to cellular models of and therapies for ocular diseases, including without limitation, the subject matters of the cellular model, gene therapy and cell therapy for BCD, of which the author is an inventor. The author would also like to note the following, which could be perceived as a conflict of interest: Invincible Vision (), a patient-led nonprofit organization focused on serving the BCD community, and ReflectionBio® have jointly launched a BCD awareness and fundraising campaign, <i>By Patients, For Patients</i>™. ReflectionBio®, <i>By Patients, For Patients</i>™ and ReflectionBio – <i>By Patients, For Patients</i>® are trademarks of Reflection Biotechnologies Limited.